Search engine for discovering works of Art, research articles, and books related to Art and Culture
Javascript must be enabled to continue!
Focal Crescentic Glomerulonephritis Superimposed on Myeloproliferative Disease-Related Glomerulopathy in a Case of Myelofibrosis
View through CrossRef
Proliferative glomerulonephritis in myelofibrosis is a very rare. Mesangial proliferation and sclerosis with changes of chronic thrombotic microangiopathy have been reported, but pauci-immune focal crescentic glomerulonephritis has not been described so far. Herein, we present a 68-year-old male who was a known case of myelofibrosis and presented with rapidly progressive glomerulonephritis and nephrotic range proteinuria. He was diagnosed as anti-neutrophil cytoplasmic antibody (ANCA)-negative focal crescentic glomerulonephritis, and he responded well to a course of intravenous methylprednisolone and cyclophosphamide. Pauci-immune focal crescentic glomerulonephritis may occur in myelofibrosis without ANCA and may be related to unknown pathogenetic mechanisms in myeloproliferative disorders or suggest any superimposed pathology that might respond well to immunosuppressants.
Title: Focal Crescentic Glomerulonephritis Superimposed on Myeloproliferative Disease-Related Glomerulopathy in a Case of Myelofibrosis
Description:
Proliferative glomerulonephritis in myelofibrosis is a very rare.
Mesangial proliferation and sclerosis with changes of chronic thrombotic microangiopathy have been reported, but pauci-immune focal crescentic glomerulonephritis has not been described so far.
Herein, we present a 68-year-old male who was a known case of myelofibrosis and presented with rapidly progressive glomerulonephritis and nephrotic range proteinuria.
He was diagnosed as anti-neutrophil cytoplasmic antibody (ANCA)-negative focal crescentic glomerulonephritis, and he responded well to a course of intravenous methylprednisolone and cyclophosphamide.
Pauci-immune focal crescentic glomerulonephritis may occur in myelofibrosis without ANCA and may be related to unknown pathogenetic mechanisms in myeloproliferative disorders or suggest any superimposed pathology that might respond well to immunosuppressants.
Related Results
FC071: An HDAC Inhibitor Attenuates Crescentic Glomerulonephritis and Avoid Chronic Kidney Disease Enhancing Podocyte Progenitor Differentiation
FC071: An HDAC Inhibitor Attenuates Crescentic Glomerulonephritis and Avoid Chronic Kidney Disease Enhancing Podocyte Progenitor Differentiation
Abstract
BACKGROUND AND AIMS
Crescentic glomerulonephritis (crescentic GN) encompasses a group of diverse disorders characterize...
Hydatid Disease of The Brain Parenchyma: A Systematic Review
Hydatid Disease of The Brain Parenchyma: A Systematic Review
Abstarct
Introduction
Isolated brain hydatid disease (BHD) is an extremely rare form of echinococcosis. A prompt and timely diagnosis is a crucial step in disease management. This ...
Could rituximab be a silver lining in refractory bone marrow fibrosis caused by lupus?
Could rituximab be a silver lining in refractory bone marrow fibrosis caused by lupus?
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease that can present with a variety of clinical manifestations, ranging from mild skin involvement to multisystemic ...
Sulfated Hyaluronic Acid, a Potential Selectin Inhibitor, Ameliorates Experimentally Induced Crescentic Glomerulonephritis
Sulfated Hyaluronic Acid, a Potential Selectin Inhibitor, Ameliorates Experimentally Induced Crescentic Glomerulonephritis
<i>Background/Aims:</i> Sulfated polysaccharides are known to interfere with the binding of selectins and their ligands. Recently, we demonstrated that sulfated hyaluro...
Crescentic Glomerulonephritis Possibly Caused by COVID-19 Infection
Crescentic Glomerulonephritis Possibly Caused by COVID-19 Infection
Background: The COVID-19 (coronavirus disease 2019) pandemic has presented a serious challenge to nephrologists, since it can lead to severe kidney injury in the form of acute tubu...
Possibilities of targeted therapy for myelofibrosis: Moscow experience
Possibilities of targeted therapy for myelofibrosis: Moscow experience
Background. For many years the primary aim of treatment strategy for ph-negative myeloproliferative neoplasms has been to restrain disease progression, with lasting relief and mana...
HMGA2 Dysregulation in Myelofibrosis with Myeloïd Metaplasia (MMM) Versus Other Phi-Negative Chronic Myeloproliferative Disorders and Myelodysplasia.
HMGA2 Dysregulation in Myelofibrosis with Myeloïd Metaplasia (MMM) Versus Other Phi-Negative Chronic Myeloproliferative Disorders and Myelodysplasia.
Abstract
Background: Dysregulation and overexpression of the tumorigenic gene HMGA2 has been demonstrated in the mononuclear cells of 12 consecutive MMM patients (pt...
Complex Collision Tumors: A Systematic Review
Complex Collision Tumors: A Systematic Review
Abstract
Introduction: A collision tumor consists of two distinct neoplastic components located within the same organ, separated by stromal tissue, without histological intermixing...